alexa Characterization Of Antiepileptic And Anxiolytic Activities Of Ethyl Acetate Fraction From Swietenia Macrophylla (SMEAF) Seeds - A Probable Medicine For Epilepsy | 64732
ISSN: 2168-975X

Brain Disorders & Therapy
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference on Neurological Disorders and Brain Injury
April 18-19, 2017 London, UK

Sayyad Mustak
Universiti Putra Malaysia, Malaysia
Jawaharlal Nehru Technological University, India
Posters & Accepted Abstracts: Brain Disord Ther
DOI: 10.4172/2168-975X-C1-015
Abstract
Epilepsy is a serious brain disorder with approximately 2.4 million new cases each year globally, from which 80% of them are in the developing world. In addition, anxiety and depression are frequent co-morbid conditions associated with epilepsy patients. Thus, developing a new agent from a plant source which may be useful in the treatment of epilepsy, along with anxiety and depression is a worthwhile approach. The main objective of this study was to characterize the potential neuropharmacological activity of ethyl acetate fraction of Swietenia macrophylla seeds (SMEAF) in experimental animal models. The results of in vitro assay suggested the ability of SMEAF in protecting primary neuronal cells against tert-butyl hydro-peroxide (TBHP) induced oxidative stress. An acute oral toxicity study was conducted in which the SMEAF was found to be safe up to the dose of 2000 mg/kg. Antiepileptic activity of SMEAF was evaluated in pentylenetetrazole (PTZ) and picrotoxin (PCT)-induced convulsion models in which important brain neurotransmitter, gamma-aminobutyric acid (GABA) levels was then estimated. SMEAF was found to have significant (p≤0.05) anticonvulsant activity and exerted its property through multiple mechanisms, indicating its anticonvulsant property through GABA receptor and also by modulating the brain monoamine levels. Furthermore, the expression of selected epilepsy associated genes in the mouse brain was investigated, where it suppressed the mRNA expression levels of selected genes after PTZ treatment. The antiepileptic activity may be due to limonoids and flavonoids which have also been reported to have various pharmacological activities in the central nervous system. The anxiolytic activity of SMEAF was evaluated in open field test and elevated plus maze. SMEAF showed significant (p≤0.05) anxiolytic activity in both tests. As SMEAF was shown to modulate the levels of GABA, this action might be contributing to the anxiolytic potential of SMEAF. The antidepressant activity was evaluated using tail suspension test, but showed no significant effect in animals treated with SMEAF as compared with the control group. Taken together, it is concluded that SMEAF may be developed as a potential therapeutic agent for the treatment of epilepsy along with anxiety.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version